Pharma News

As Gilead gears up to launch filgotinib, the JAK inhibitor it has under FDA review in rheumatoid arthritis, it knows full well it’s prepping for entry into a crowded market.

Horizon Therapeutics is trying to shed its reputation as a primary care drugmaker and emerge with a brand-new life in rare diseases.

As fears about the spread of a new coronavirus grip communities ranging from Washington State in the U.

Scientists have been testing various ways to tackle neurodegenerative diseases—blocking the production of toxic proteins, regenerating functional neurons and restoring the brain’s waste-clearing s...

To better treat people with depression, not only must we treat the neurons affected by the disease, but we must also restore the integrity of the barrier that regulates exchanges between blood circula...

A U .

Eli Lilly has been stuffing its pipeline with a host of assets and has decided it needs a new injectables drug and device plant to squeeze them out the other end, assuming they are approved.

The European Commission has approved Roche’s Polivy (polatuzumab vedotin) for people with previously treated aggressive lymphoma.

A new report from GlobalData has estimated that the global heart failure (HF) market is expected to grow from $3.

Certain surgical gowns and surgical packs made by Cardinal Health may not be sterile and should not be used, the U.

BEIJING, Jan.

China reported Monday a sharp rise in the number of people infected with a new coronavirus, including the first cases in the capital.